If you purchase this report now and we update it in next 100 days, get it free!
Key Insights
• The UK represents a massive cornerstone of the European diagnostics sector, capturing significant portion of the entire European immunoassay market share. Within this domestic footprint, the market is heavily characterized by a reliance on recurring consumables (reagents, monoclonal antibodies, and test kits), which capture approximately 62% of the market value, outstripping capital hardware sales due to continuous diagnostic runs across NHS Trust networks.
• A major breakthrough accelerating the UK immunoassay market is a $1 billion commitment from BioNTech to expand its personalized oncology research capabilities in the country. Backed by a UK government grant, this massive deployment of R&D facilities directly scales up the national clinical demand for ultra-high-sensitivity Research Use Only (RUO) immunoassay kits and specialized tumor-associated antigen biomarker panels.
• The baseline utilization of immunoassay testing in the UK is heavily tied to systemic epidemiological demands. Long-term chronic conditions such as diabetes, autoimmune disorders, and cardiovascular illnesses currently account for approximately 70% of all deaths in the UK. This statistical reality forces NHS clinical pathways to absorb immense volumes of routine immunoassay monitoring panels to track disease progression and therapeutic efficacy.
Market Outlook
• According to the research report, "UK Immunoassays Market Outlook, 2031," published by Bonafide Research, the UK Immunoassays Market is anticipated to grow at more than 4.81% CAGR from 2026 to 2031.
• Driven by an immediate need to shorten hospital wait times and reduce the backlogs in centralized laboratories, the UK outlook points toward rapid procurement of portable, benchtop fluorescent and lateral-flow point-of-care immunoassay platforms. These user-friendly devices are migrating advanced diagnostic capabilities directly into local GP practices, community pharmacies, and urgent care clinics across England's Golden Triangle.
• The operational landscape is shifting toward smart microplate readers and chemiluminescent systems paired with AI data-management software. To satisfy strict UK GDPR and national health data security frameworks, new immunoassay software deployments are transitioning toward Zero-Trust architectures that automate the validation and risk-scoring of protein interaction assays, transforming raw qualitative results into secure, interoperable data logs.
• The UK market operates under strict technical and data oversight from bodies like the British In Vitro Diagnostics Association (BIVDA) and the Medicines and Healthcare products Regulatory Agency (MHRA). The commercial landscape is led by dominant multinational and prominent domestic players, including Abcam PLC, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Danaher Corporation (Beckman Coulter).
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Driver: NHS diagnostic hub consolidation and faster cancer diagnostic pathways
The primary accelerator for the UK immunoassay market is the continuous structural restructuring of NHS diagnostics through Community Diagnostic Centres (CDCs) and the Rapid Diagnostic Centre (RDC) framework. To meet strict NHS targets such as the 28-Day Faster Diagnosis Standard for cancer public healthcare procurement is heavily favoring high-volume, automated immunoassay screening. This structural change drives immense, consistent testing volume for tumor markers and cardiac panels across a unified network of regional clinical hubs. Challenge: Regulatory fragmentation and approved body capacity
The most significant hurdle facing the UK immunoassay sector is navigating the diverging post-Brexit regulatory frameworks between Great Britain (regulated by the MHRA) and Northern Ireland (which still adheres to the EU IVDR). While the MHRA allows extended transitional recognition for European CE-marked IVDs until June 30, 2030, manufacturers face an immediate operational bottleneck: a severe national shortage of domestic UK Approved Bodies capable of auditing and issuing local UKCA conformity assessments, creating long-term market access uncertainty for mid-tier diagnostic vendors. Trend: Emergence of the international reliance pathway & AI diagnostics
A major market trend is the rapid structural pivot toward the MHRA’s freshly drafted International Reliance Pathway. Rather than forcing manufacturers to run duplicate local trials, the UK framework allows qualifying immunoassay devices authorized by comparable global regulators such as the US FDA or Health Canada to secure an accelerated route to the Great Britain market. Concurrently, these platforms are increasingly paired with mandatory Unique Device Identifiers (UDI) and AI data tools, integrating immunoassay data securely into NHS electronic systems.
Policies
• Mandatory MHRA Device Registration: Every immunoassay system, analyzer hardware unit, and reagent kit must be formally registered within the MHRA’s centralized device database before it can be commercially deployed or utilized in Great Britain.
• Appointment of a UK Responsible Person (UKRP): Foreign manufacturers without a physical, legal corporate establishment in the UK are legally prohibited from registering devices directly. They must appoint a designated UKRP based in Great Britain to register the immunoassay products, validate technical documentation, and assume direct post-market surveillance liabilities.
• The Upcoming Risk-Based Class A-D Overhaul: Under the draft Medical Devices Regulations, the UK is actively transitioning away from its old list-based framework to a strict, 4-tier risk classification system (Classes A to D). Manufacturers must prepare for sudden upward reclassifications.
• Compliance with the 2025 Post-Market Surveillance (PMS) Law: Immunoassay providers must comply with the strict PMS regulations that entered into full force in mid-2025. This mandate forces companies to maintain enhanced, proactive data collection systems, execute stringent electronic reporting protocols for safety incidents, and provide exhaustive, periodic safety update logs directly to the MHRA.
Segment Analysis
Make this report your own
Have queries/questions regarding a report
Take advantage of intelligence tailored to your business objective
Sikandar Kesari
Research Analyst
UK Immunoassays By Technology
• Chemiluminescence immunoassays represent the preferred technology in large NHS pathology laboratories because they combine rapid turnaround with high analytical sensitivity. Their compatibility with fully automated laboratory analyzers allows continuous sample processing, making them particularly suitable for high-volume hospital settings. UK laboratories increasingly favor CLIA platforms capable of running multiple disease panels simultaneously, reducing instrument downtime and improving laboratory workflow.
• ELISA continues to maintain a significant role despite increasing laboratory automation. Many UK reference laboratories, university hospitals, and public health laboratories rely on ELISA because of its flexibility in developing laboratory-developed tests and validating emerging biomarkers.
• Fluorescence-based immunoassays have expanded within UK healthcare due to their application in rapid diagnostics and decentralized testing environments. Their ability to deliver accurate quantitative results within shorter testing windows makes them attractive for emergency departments, outpatient clinics, and near-patient testing services.
• Radioimmunoassays occupy a niche position in the UK market because of regulatory requirements surrounding radioactive materials and specialized laboratory infrastructure. Most routine diagnostic laboratories have transitioned toward non-radioactive technologies that provide comparable analytical performance with simpler operational requirements.
• ELISpot technology is increasingly associated with advanced immune function assessment rather than routine clinical diagnostics. UK academic medical centres utilize ELISpot extensively in immunology research, vaccine evaluation, and cellular immune response studies.
• Western blot remains an important confirmatory technology in selected diagnostic pathways despite declining routine utilization. UK specialist laboratories employ Western blot primarily where additional protein-specific confirmation is required following initial screening tests.
UK Immunoassays By Application
• Infectious disease testing remains one of the strongest application areas due to continuous surveillance of respiratory viruses, blood-borne pathogens, sexually transmitted infections, and healthcare-associated infections. UK laboratories increasingly prioritize assays that can rapidly differentiate multiple pathogens while supporting national public health monitoring programs.
• Endocrinology testing represents a mature immunoassay application driven by routine assessment of thyroid disorders, reproductive hormones, adrenal function, and metabolic diseases. Automation is particularly valued because endocrine biomarkers require highly reproducible quantitative measurements for long-term patient monitoring.
• Cancer diagnostics increasingly utilize immunoassays for tumor marker assessment, treatment monitoring, and recurrence surveillance. UK oncology services are integrating biomarker testing more closely with personalized treatment pathways, encouraging wider adoption of highly sensitive immunoassay technologies alongside molecular diagnostics.
• Cardiology testing continues to expand as NHS services emphasize rapid diagnosis of acute cardiovascular events. High-sensitivity cardiac biomarkers have become central components of emergency care pathways, enabling clinicians to make faster decisions regarding patient admission, discharge, or further investigation.
• Autoimmune diagnostics require highly specific antibody detection because many disorders present with overlapping clinical symptoms. UK specialist laboratories increasingly employ immunoassay panels capable of evaluating multiple autoantibodies simultaneously, supporting earlier diagnosis and improved disease classification.
UK Immunoassays By Product
• Reagents and kits represent the operational foundation of immunoassay testing because laboratories require continuous replenishment for routine diagnostic services. UK laboratories increasingly prefer standardized reagent systems that offer long shelf life, consistent lot-to-lot performance, and compatibility with automated analyzers operating across regional pathology networks.
• Instrument demand is shifting toward fully automated, high-throughput analyzers capable of integrating multiple immunoassay technologies within a single platform. NHS laboratory consolidation has accelerated investment in systems that maximize productivity, reduce manual intervention, and support centralized testing across multiple healthcare facilities.
• Software has become increasingly important as pathology laboratories digitize workflow management and quality assurance processes. Modern immunoassay platforms increasingly incorporate laboratory information system integration, remote instrument monitoring, predictive maintenance, and automated quality control.
Don't pay for what you don't need. Save 30%
Customise your report by selecting specific countries or regions
UK Immunoassays By End-User
• Hospitals and clinics remain the primary users of immunoassays due to the broad range of routine diagnostic tests performed across emergency medicine, endocrinology, oncology, cardiology, and infectious disease departments. Increasing emphasis on rapid clinical decision-making has encouraged adoption of highly automated systems capable of delivering consistent results with minimal manual handling.
• Clinical laboratories constitute the largest centralized testing environment within the UK immunoassay market. Regional pathology networks have accelerated laboratory consolidation, allowing centralized facilities to process higher testing volumes while improving operational efficiency and standardizing diagnostic practices across multiple NHS organizations.
• Blood banks rely extensively on immunoassays for donor screening and transfusion safety. UK blood services maintain stringent testing protocols to identify transfusion-transmissible infections before blood products enter clinical use. Continuous improvements in assay sensitivity contribute to maintaining high standards of blood safety and public confidence in national blood donation programs.
• Pharmaceutical and biotechnology companies utilize immunoassays throughout drug discovery, biomarker validation, clinical trials, and biologics development. Growing activity in immunotherapy, vaccine development, and precision medicine research has increased demand for specialized immunoassay platforms capable of supporting complex biomarker analysis and translational research.
• Other end users include academic research institutions, public health laboratories, veterinary diagnostic centres, forensic laboratories, and contract research organizations. These organizations often require specialized immunoassay platforms for exploratory research, epidemiological surveillance, assay development, and advanced biomarker discovery, contributing to ongoing innovation within the UK immunoassay ecosystem.
Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031
Aspects covered in this report
• Immunoassays Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation
By Technology
• Chemiluminescence Immunoassays (CLIA)
• Enzyme Immunoassays (ELISA/EIA)
• Fluorescence Immunoassays (FIA/IFA/ELFA)
• Radioimmunoassays (RIA)
• Rapid/Lateral Flow Immunoassays
• ELISpot
• Western Blot
• Multiplex & Other Immunoassays
By Application
• Infectious Disease Testing
• Endocrinology Testing
• Oncology Testing
• Cardiology Testing
• Autoimmune Disease Testing
• Therapeutic Drug Monitoring
• Allergy Diagnostics
• Other Applications
By End User
• Hospitals & Clinics
• Clinical Laboratories
• Blood Banks
• Pharmaceutical & Biotechnology Companies
• Others
Table of Contents
1. Executive Summary
2. Market Structure
2.1. Market Considerate
2.2. Assumptions
2.3. Limitations
2.4. Abbreviations
2.5. Sources
2.6. Definitions
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. UK Geography
4.1. Population Distribution Table
4.2. UK Macro Economic Indicators
5. Market Dynamics
5.1. Key Insights
5.2. Recent Developments
5.3. Market Drivers & Opportunities
5.4. Market Restraints & Challenges
5.5. Market Trends
5.6. Supply chain Analysis
5.7. Policy & Regulatory Framework
5.8. Industry Experts Views
6. UK Immunoassays Market Overview
6.1. Market Size By Value
6.2. Market Size and Forecast, By Technology
6.3. Market Size and Forecast, By Application
6.4. Market Size and Forecast, By Product
6.5. Market Size and Forecast, By End User
6.6. Market Size and Forecast, By Region
7. UK Immunoassays Market Segmentations
7.1. UK Immunoassays Market, By Technology
7.1.1. UK Immunoassays Market Size, By Chemiluminescence Immunoassays (CLIA), 2020-2031
7.1.2. UK Immunoassays Market Size, By Enzyme Immunoassays (ELISA/EIA), 2020-2031
7.1.3. UK Immunoassays Market Size, By Fluorescence Immunoassays (FIA/IFA/ELFA), 2020-2031
7.1.4. UK Immunoassays Market Size, By Radioimmunoassays (RIA), 2020-2031
7.1.5. UK Immunoassays Market Size, By Rapid/Lateral Flow Immunoassays, 2020-2031
7.1.6. UK Immunoassays Market Size, By ELISpot, 2020-2031
7.1.7. UK Immunoassays Market Size, By Western Blot, 2020-2031
7.1.8. UK Immunoassays Market Size, By Multiplex & Other Immunoassays, 2020-2031
7.2. UK Immunoassays Market, By Application
7.2.1. UK Immunoassays Market Size, By Infectious Disease Testing, 2020-2031
7.2.2. UK Immunoassays Market Size, By Endocrinology Testing, 2020-2031
7.2.3. UK Immunoassays Market Size, By Oncology Testing, 2020-2031
7.2.4. UK Immunoassays Market Size, By Cardiology Testing, 2020-2031
7.2.5. UK Immunoassays Market Size, By Autoimmune Disease Testing, 2020-2031
7.2.6. UK Immunoassays Market Size, By Therapeutic Drug Monitoring, 2020-2031
7.2.7. UK Immunoassays Market Size, By Allergy Diagnostics, 2020-2031
7.2.8. UK Immunoassays Market Size, By Other Applications, 2020-2031
7.3. UK Immunoassays Market, By Product
7.3.1. UK Immunoassays Market Size, By Reagents & Kits, 2020-2031
7.3.2. UK Immunoassays Market Size, By Analyzers & Instruments, 2020-2031
7.3.3. UK Immunoassays Market Size, By Software & Services, 2020-2031
7.4. UK Immunoassays Market, By End User
7.4.1. UK Immunoassays Market Size, By Hospitals & Clinics, 2020-2031
7.4.2. UK Immunoassays Market Size, By Clinical Laboratories, 2020-2031
7.4.3. UK Immunoassays Market Size, By Blood Banks, 2020-2031
7.4.4. UK Immunoassays Market Size, By Pharmaceutical & Biotechnology Companies, 2020-2031
7.4.5. UK Immunoassays Market Size, By Others, 2020-2031
7.5. UK Immunoassays Market, By Region
7.5.1. UK Immunoassays Market Size, By North, 2020-2031
7.5.2. UK Immunoassays Market Size, By East, 2020-2031
7.5.3. UK Immunoassays Market Size, By West, 2020-2031
7.5.4. UK Immunoassays Market Size, By South, 2020-2031
8. UK Immunoassays Market Opportunity Assessment
8.1. By Technology, 2026 to 2031
8.2. By Application, 2026 to 2031
8.3. By Product, 2026 to 2031
8.4. By End User, 2026 to 2031
8.5. By Region, 2026 to 2031
9. Competitive Landscape
9.1. Porter's Five Forces
9.2. Company Profile
9.2.1. Company 1
9.2.1.1. Company Snapshot
9.2.1.2. Company Overview
9.2.1.3. Financial Highlights
9.2.1.4. Geographic Insights
9.2.1.5. Business Segment & Performance
9.2.1.6. Product Portfolio
9.2.1.7. Key Executives
9.2.1.8. Strategic Moves & Developments
9.2.2. Company 2
9.2.3. Company 3
9.2.4. Company 4
9.2.5. Company 5
9.2.6. Company 6
9.2.7. Company 7
9.2.8. Company 8
10. Strategic Recommendations
11. Disclaimer
Table 1: Influencing Factors for Immunoassays Market, 2025
Table 2: UK Immunoassays Market Size and Forecast, By Technology (2020 to 2031F) (In USD Million)
Table 3: UK Immunoassays Market Size and Forecast, By Application (2020 to 2031F) (In USD Million)
Table 4: UK Immunoassays Market Size and Forecast, By Product (2020 to 2031F) (In USD Million)
Table 5: UK Immunoassays Market Size and Forecast, By End User (2020 to 2031F) (In USD Million)
Table 6: UK Immunoassays Market Size and Forecast, By Region (2020 to 2031F) (In USD Million)
Table 7: UK Immunoassays Market Size of Chemiluminescence Immunoassays (CLIA) (2020 to 2031) in USD Million
Table 8: UK Immunoassays Market Size of Enzyme Immunoassays (ELISA/EIA) (2020 to 2031) in USD Million
Table 9: UK Immunoassays Market Size of Fluorescence Immunoassays (FIA/IFA/ELFA) (2020 to 2031) in USD Million
Table 10: UK Immunoassays Market Size of Radioimmunoassays (RIA) (2020 to 2031) in USD Million
Table 11: UK Immunoassays Market Size of Rapid/Lateral Flow Immunoassays (2020 to 2031) in USD Million
Table 12: UK Immunoassays Market Size of ELISpot (2020 to 2031) in USD Million
Table 13: UK Immunoassays Market Size of Western Blot (2020 to 2031) in USD Million
Table 14: UK Immunoassays Market Size of Multiplex & Other Immunoassays (2020 to 2031) in USD Million
Table 15: UK Immunoassays Market Size of Infectious Disease Testing (2020 to 2031) in USD Million
Table 16: UK Immunoassays Market Size of Endocrinology Testing (2020 to 2031) in USD Million
Table 17: UK Immunoassays Market Size of Oncology Testing (2020 to 2031) in USD Million
Table 18: UK Immunoassays Market Size of Cardiology Testing (2020 to 2031) in USD Million
Table 19: UK Immunoassays Market Size of Autoimmune Disease Testing (2020 to 2031) in USD Million
Table 20: UK Immunoassays Market Size of Therapeutic Drug Monitoring (2020 to 2031) in USD Million
Table 21: UK Immunoassays Market Size of Allergy Diagnostics (2020 to 2031) in USD Million
Table 22: UK Immunoassays Market Size of Other Applications (2020 to 2031) in USD Million
Table 23: UK Immunoassays Market Size of Reagents & Kits (2020 to 2031) in USD Million
Table 24: UK Immunoassays Market Size of Analyzers & Instruments (2020 to 2031) in USD Million
Table 25: UK Immunoassays Market Size of Software & Services (2020 to 2031) in USD Million
Table 26: UK Immunoassays Market Size of Hospitals & Clinics (2020 to 2031) in USD Million
Table 27: UK Immunoassays Market Size of Clinical Laboratories (2020 to 2031) in USD Million
Table 28: UK Immunoassays Market Size of Blood Banks (2020 to 2031) in USD Million
Table 29: UK Immunoassays Market Size of Pharmaceutical & Biotechnology Companies (2020 to 2031) in USD Million
Table 30: UK Immunoassays Market Size of Others (2020 to 2031) in USD Million
Table 31: UK Immunoassays Market Size of North (2020 to 2031) in USD Million
Table 32: UK Immunoassays Market Size of East (2020 to 2031) in USD Million
Table 33: UK Immunoassays Market Size of West (2020 to 2031) in USD Million
Table 34: UK Immunoassays Market Size of South (2020 to 2031) in USD Million
Figure 1: UK Immunoassays Market Size By Value (2020, 2025 & 2031F) (in USD Million)
Figure 2: Market Attractiveness Index, By Technology
Figure 3: Market Attractiveness Index, By Application
Figure 4: Market Attractiveness Index, By Product
Figure 5: Market Attractiveness Index, By End User
Figure 6: Market Attractiveness Index, By Region
Figure 7: Porter's Five Forces of UK Immunoassays Market
United Kingdom Immunoassay Market Research FAQs
They are used to detect biomarkers for diagnosing infectious diseases, cancer, endocrine disorders, autoimmune diseases, and cardiovascular conditions.
They improve data management, regulatory compliance, workflow automation, and instrument performance across diagnostic laboratories.
Saliva enables convenient, non-invasive sample collection while supporting reliable biomarker analysis for multiple clinical applications.
Pharmaceutical companies, biotechnology firms, hospitals, diagnostic laboratories, and academic research institutes are the primary end users.
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information